Skip to main content

Table 2 Demographic and clinical characteristics of reported Crohn’s disease patients with hepatosplenic T-cell lymphoma (HSTCL)

From: Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma

 

Unique cases (n = 37)

Cases with insufficient reportinga(n = 9)

Age at HSTCL diagnosis, years

n = 36

n = 0

Mean

30

-

Median

26

-

Range

12 to 79

-

Disease duration, years

n = 16

n = 0

Mean

10

-

Median

6

-

Range

4 to 35

-

Sex, n (%)

n = 36

n = 6

Female

5 (14%)

1 (17%)

Survival, n (%)

n = 26

n = 4

Died

24 (92%)

4 (100%)

Survived

2 (8%)

0 (0%)

Physical examination and laboratory abnormalities at time of HSTCL diagnosis, n (%)

n = 19

n = 1

Hepatosplenomegaly or splenomegaly

19 (100%)

1 (100%)

Fever

9 (47%)

-

Cytopenia of any type

11 (58%)

-

Altered liver enzymes and/or LDH

5 (26%)

-

  1. aInsufficient reporting on demographic information prevented us from identifying if the cases were unique. With each patient characteristic heading, the adjacent ‘n = x’ cells indicate the number of cases that reported on that particular demographic. The percentages calculated for sex, survival, and physical examination/laboratory abnormalities use this ‘n’ as the denominator. HSTCL, hepatosplenic T-cell lymphoma, LDH, lactate dehydrogenase.